Interferon Gamma-1B Dosage

Medically reviewed by Drugs.com. Last updated on Feb 13, 2023.

Usual Adult Dose for Chronic Granulomatous Disease

Body surface area (BSA) 0.5 m2 or less:
1.5 mcg/kg/dose subcutaneously 3 times a week

BSA greater than 0.5 m2:
50 mcg/m2 (1 million International Units/m2) subcutaneously 3 times a week

Comments:

• Prior to the beginning of treatment and at 3-month intervals during treatment the following laboratory tests are recommended for all patients: hematologic tests (including complete blood counts), differential and platelet counts, blood chemistries (including renal and liver function tests), and urinalysis.

Use: For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD)

Usual Adult Dose for Osteopetrosis

Body surface area (BSA) 0.5 m2 or less:
1.5 mcg/kg/dose subcutaneously 3 times a week

BSA greater than 0.5 m2:
50 mcg/m2 (1 million International Units/m2) subcutaneously 3 times a week

Comments:

• Prior to the beginning of treatment and at 3-month intervals during treatment the following laboratory tests are recommended for all patients: hematologic tests (including complete blood counts), differential and platelet counts, blood chemistries (including renal and liver function tests), and urinalysis.

Use: For delaying time to disease progression in patients with severe malignant osteopetrosis (SMO)

Usual Pediatric Dose for Chronic Granulomatous Disease

One year and older:

• Body surface area (BSA) 0.5 m2 or less:

1.5 mcg/kg/dose subcutaneously 3 times a week

• BSA greater than 0.5 m2:

50 mcg/m2 (1 million International Units/m2) subcutaneously 3 times a week

Comments:

• Prior to the beginning of treatment and at 3-month intervals during treatment the following laboratory tests are recommended for all patients: Hematologic tests (including complete blood counts), differential and platelet counts, blood chemistries (including renal and liver function tests) and urinalysis. In patients less than 1 year, liver function tests should be measured monthly.

Use: For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD) in children 1 year and older

Usual Pediatric Dose for Osteopetrosis

One month and older:

• Body surface area (BSA) 0.5 m2 or less:

1.5 mcg/kg/dose subcutaneously 3 times a week

• BSA greater than 0.5 m2:

50 mcg/m2 (1 million International Units/m2) subcutaneously 3 times a week

Comments:

• Prior to the beginning of treatment and at 3-month intervals during treatment the following laboratory tests are recommended for all patients: Hematologic tests (including complete blood counts), differential and platelet counts, blood chemistries (including renal and liver function tests) and urinalysis. In patients less than 1 year, liver function tests should be measured monthly.

Use: For delaying time to disease progression in patients with severe malignant osteopetrosis (SMO) in children 1 month and older

Renal Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Liver Dose Adjustments

Reduce dose or discontinue therapy to reverse severe elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT). Monitor liver function monthly in patients less than 1 year old.

Dose Adjustments

Dose Modification:

• If severe reactions occur, the dose should be reduced by 50% or therapy should be interrupted until the adverse reaction abates.
• Safety and efficacy have not been established for this drug given in doses greater or less than the recommended dose of 50 mcg/m2. Higher doses (i.e., greater than 50 mcg/m2) are not recommended. The minimum effective dose has not been established.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Hypersensitivity to interferon gamma or E. coli derived products

Safety and efficacy have not been established in patients younger than 1 year for chronic granulomatous disease (CGD).
Safety and efficacy have not been established in patients younger than 1 month for severe malignant osteopetrosis (SMO).

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug can be administered by a physician, nurse, family member, or patient when counseled in the administration of subcutaneous injections.
• The optimum sites of subcutaneous injection are the right and left deltoid and anterior thigh.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
• This drug is for a single use only.
• Discard any unused portion.
• Do not mix other drugs with this drug in the same syringe.
• Administer this drug using either sterilized glass or plastic disposable syringes.

Storage requirements:

• Store vials in the refrigerator at 2C to 8C (36F to 46F).
• Do not freeze.
• Avoid excessive or vigorous agitation. Do not shake.
• An unused vial can be stored at room temperature up to 12 hours prior to use.
• Discard vials if not used within a 12-hour period. Do not return to the refrigerator.

Monitoring:

• When administering this drug in combination with other potentially myelosuppressive agents, monitor neutrophil and platelet counts.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer